Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 3;11(1):6.
doi: 10.1167/tvst.11.1.6.

Prevalence of RPGR-Mediated Retinal Dystrophy in an Unselected Cohort of Over 5000 Patients

Sari Tuupanen  1 , Kimberly Gall  2 , Johanna Sistonen  1 , Inka Saarinen  1 , Kati Kämpjärvi  1 , Kirsty Wells  1 , Katja Merkkiniemi  1 , Pernilla von Nandelstadh  1 , Laura Sarantaus  1 , Johanna Känsäkoski  1 , Emma Mårtenson  1 , Hanna Västinsalo  1 , Jennifer Schleit  2 , Eeva-Marja Sankila  3 , Annakarin Kere  1 , Heidi Junnila  1 , Pauli Siivonen  1 , Margarita Andreevskaya  1 , Ville Kytölä  1 , Mikko Muona  1 , Pertteli Salmenperä  1 , Samuel Myllykangas  1 , Juha Koskenvuo  1 , Tero-Pekka Alastalo  2
Affiliations

Prevalence of RPGR-Mediated Retinal Dystrophy in an Unselected Cohort of Over 5000 Patients

Sari Tuupanen et al. Transl Vis Sci Technol. .

Abstract

Purpose: Comprehensive genetic testing for inherited retinal dystrophy (IRD) is challenged by difficult-to-sequence genomic regions, which are often mutational hotspots, such as RPGR ORF15. The purpose of this study was to evaluate the diagnostic contribution of RPGR variants in an unselected IRD patient cohort referred for testing in a clinical diagnostic laboratory.

Methods: A total of 5201 consecutive patients were analyzed with a clinically validated next-generation sequencing (NGS)-based assay, including the difficult-to-sequence RPGR ORF15 region. Copy number variant (CNV) detection from NGS data was included. Variant interpretation was performed per the American College of Medical Genetics and Genomics guidelines.

Results: A confirmed molecular diagnosis in RPGR was found in 4.5% of patients, 24.0% of whom were females. Variants in ORF15 accounted for 74% of the diagnoses; 29% of the diagnostic variants were in the most difficult-to-sequence central region of ORF15 (c.2470-3230). Truncating variants made up the majority (91%) of the diagnostic variants. CNVs explained 2% of the diagnostic cases, of which 80% were one- or two-exon deletions outside of ORF15.

Conclusions: Our findings indicate that high-throughput, clinically validated NGS-based testing covering the difficult-to-sequence region of ORF15, in combination with high-resolution CNV detection, can help to maximize the diagnostic yield for patients with IRD.

Translational relevance: These results demonstrate an accurate and scalable method for the detection of RPGR-related variants, including the difficult-to-sequence ORF15 hotspot, which is relevant given current and emerging therapeutic opportunities.

PubMed Disclaimer

Conflict of interest statement

Disclosure: S. Tuupanen, Blueprint Genetics Blueprint Genetics (E); K. Gall, Blueprint Genetics (E); J. Sistonen, Blueprint Genetics (E); I. Saarinen, Blueprint Genetics (E); K. Kämpjärvi, Blueprint Genetics (E); K. Wells, Blueprint Genetics (E); K. Merkkiniemi, Blueprint Genetics (E); P. von Nandelstadh, Blueprint Genetics (E); L. Sarantaus, Blueprint Genetics (E); J. Känsäkoski, Blueprint Genetics (E); E. Mårtenson, Blueprint Genetics (E); H. Västinsalo, Blueprint Genetics (E); J. Schleit, Blueprint Genetics (E); E.-M. Sankila, Blueprint Genetics (C); Novartis (C, R); Biogen (C, R) and Bayer (C, R); A. Kere, Blueprint Genetics (E); H. Junnila, Blueprint Genetics (E); P. Siivonen, Blueprint Genetics (E); M. Andreevskaya, Blueprint Genetics (E); V. Kytölä, Blueprint Genetics (E); M. Muona, Blueprint Genetics (E); P. Salmenperä, Blueprint Genetics (E); S. Myllykangas, Blueprint Genetics (E); J. Koskenvuo, Blueprint Genetics (E); T.-P. Alastalo, Blueprint Genetics (E)

Figures

Figure.
Figure.
RPGR variant characteristics in 234 diagnostic cases. (a) Distribution of variants by location in the gene. ORF15 central region encompasses c.2470-3230, p.824–1077. (b) Variant type.
See this image and copyright information in PMC

References

    1. Daiger SP, Bowne SJ, Sullivan LS.. Perspective on genes and mutations causing retinitis pigmentosa. Arch Ophthalmol. 2007; 125(2): 151–158, doi:10.1001/archopht.125.2.151. - DOI - PMC - PubMed
    1. Churchill JD, Bowne SJ, Sullivan LS, et al. .. Mutations in the X-linked retinitis pigmentosa genes RPGR and RP2 found in 8.5% of families with a provisional diagnosis of autosomal dominant retinitis pigmentosa mutations in X-linked retinitis pigmentosa genes. Invest Ophth Vis Sci. 2013; 54(2): 1411–1416, doi:10.1167/iovs.12-11541. - DOI - PMC - PubMed
    1. Wang J, Zhang VW, Feng Y, et al. .. Dependable and efficient clinical utility of target capture-based deep sequencing in molecular diagnosis of retinitis pigmentosa targeted capture-based NGS analysis of RP genes. Invest Ophth Vis Sci. 2014; 55(10): 6213–6223, doi:10.1167/iovs.14-14936. - DOI - PubMed
    1. Li J, Tang J, Feng Y, et al. .. Improved diagnosis of inherited retinal dystrophies by high-fidelity PCR of ORF15 followed by next-generation sequencing. J Mol Diagnostics. 2016; 18(6): 817–824, doi:10.1016/j.jmoldx.2016.06.007. - DOI - PubMed
    1. Branham K, Othman M, Brumm M, et al. .. Mutations in RPGR and RP2 account for 15% of males with simplex retinal degenerative disease X-linked mutations in simplex males. Invest Ophth Vis Sci. 2012; 53(13): 8232–8237, doi:10.1167/iovs.12-11025. - DOI - PMC - PubMed